HC Wainwright Weighs in on Verastem FY2025 Earnings

Verastem, Inc. (NASDAQ:VSTM) – Investment analysts at HC Wainwright issued their FY2025 earnings per share (EPS) estimates for Verastem in a report issued on Wednesday, February 4th. HC Wainwright analyst A. Maldonado anticipates that the biopharmaceutical company will earn ($3.21) per share for the year. HC Wainwright has a “Buy” rating and a $18.00 price target on the stock. The consensus estimate for Verastem’s current full-year earnings is ($3.02) per share. HC Wainwright also issued estimates for Verastem’s Q4 2025 earnings at ($0.52) EPS, Q1 2026 earnings at ($0.49) EPS, Q2 2026 earnings at ($0.49) EPS, Q3 2026 earnings at ($0.47) EPS, Q4 2026 earnings at ($0.41) EPS, FY2026 earnings at ($1.86) EPS, FY2027 earnings at ($0.44) EPS, FY2028 earnings at $0.29 EPS and FY2029 earnings at $0.89 EPS.

Several other equities research analysts have also commented on the company. Mizuho set a $15.00 price objective on Verastem in a research report on Wednesday, October 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of Verastem in a report on Wednesday, January 21st. Wall Street Zen lowered shares of Verastem from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Cantor Fitzgerald upgraded shares of Verastem to a “strong-buy” rating in a research report on Thursday, October 30th. Finally, Guggenheim reissued a “buy” rating on shares of Verastem in a research note on Tuesday, December 30th. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Verastem presently has a consensus rating of “Moderate Buy” and a consensus price target of $15.83.

Verastem Stock Performance

Shares of VSTM stock opened at $6.67 on Friday. Verastem has a 52-week low of $4.01 and a 52-week high of $11.24. The company has a quick ratio of 2.55, a current ratio of 2.58 and a debt-to-equity ratio of 2.06. The stock has a market cap of $445.42 million, a PE ratio of -1.66 and a beta of 0.41. The business has a 50-day simple moving average of $7.75 and a 200-day simple moving average of $8.26.

Verastem (NASDAQ:VSTM) last posted its earnings results on Tuesday, November 4th. The biopharmaceutical company reported ($1.35) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.84). The company had revenue of $11.24 million for the quarter, compared to the consensus estimate of $5.76 million.

Institutional Investors Weigh In On Verastem

A number of hedge funds have recently modified their holdings of VSTM. Russell Investments Group Ltd. raised its holdings in Verastem by 182.9% in the 3rd quarter. Russell Investments Group Ltd. now owns 4,578 shares of the biopharmaceutical company’s stock valued at $40,000 after acquiring an additional 2,960 shares during the last quarter. E Fund Management Co. Ltd. purchased a new stake in shares of Verastem in the second quarter valued at approximately $49,000. Nebula Research & Development LLC purchased a new stake in shares of Verastem in the second quarter valued at approximately $53,000. The Manufacturers Life Insurance Company increased its holdings in shares of Verastem by 9.8% in the second quarter. The Manufacturers Life Insurance Company now owns 16,188 shares of the biopharmaceutical company’s stock valued at $67,000 after purchasing an additional 1,440 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its position in Verastem by 110.9% during the third quarter. BNP Paribas Financial Markets now owns 8,550 shares of the biopharmaceutical company’s stock worth $75,000 after buying an additional 4,496 shares in the last quarter. 88.37% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Verastem

In other news, CFO Daniel Calkins sold 5,039 shares of Verastem stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $7.16, for a total value of $36,079.24. Following the sale, the chief financial officer directly owned 104,719 shares of the company’s stock, valued at $749,788.04. The trade was a 4.59% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Dan Paterson sold 10,321 shares of the business’s stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $7.16, for a total value of $73,898.36. Following the sale, the chief executive officer owned 400,104 shares of the company’s stock, valued at $2,864,744.64. The trade was a 2.51% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 50,478 shares of company stock valued at $462,045. 2.10% of the stock is owned by corporate insiders.

Key Verastem News

Here are the key news stories impacting Verastem this week:

• Positive Sentiment: Preliminary Q4 and full‑year 2025 revenue came in stronger than investors expected, driven by sales from the Avmapki Fakzynja co‑pack partnership; the release prompted the near‑term stock rally. Verastem preliminary results
• Positive Sentiment: HC Wainwright reiterated a “Buy” rating and an $18 price target and updated long‑range EPS forecasts — notably raising FY2028 and FY2029 estimates and projecting much larger positive EPS by FY2030 — signaling growing analyst confidence in Verastem’s path to profitability. This analyst support likely amplified buying interest. HC Wainwright estimates (MarketBeat)
• Neutral Sentiment: CEO Dan Paterson filed a small sale of 970 shares at about $6.69 on Feb. 4; the sale is modest relative to his remaining holdings and likely has limited informational weight for investors. SEC filing
• Negative Sentiment: HC Wainwright’s near‑term forecasts still show multi‑year losses (FY2025–FY2027 and FY2026 EPS pegged negative), so while long‑term outlook is improving, the company remains unprofitable in the medium term — a risk for investors focused on near‑term cash burn or dilution. HC Wainwright estimates (MarketBeat)

Verastem Company Profile

Verastem Oncology, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapies that target cancer stemness and resistance pathways. Established in 2010 and headquartered in Needham, Massachusetts, Verastem Oncology applies a precision-medicine approach to identify key signaling nodes responsible for tumor growth and relapse, with an emphasis on hematologic malignancies and solid tumors. The company’s research platform integrates insights into complex signaling networks to advance novel compounds from early discovery through clinical proof of concept.

The company’s lead marketed product is COPIKTRA (duvelisib), an oral inhibitor of PI3K-delta and PI3K-gamma, which received U.S.